*1 pt allocated to B received FP in error (summarized in C for safety) CPS, combined positive score; NA, not applicable Conclusions Combination of T-DXd + FP + pembro showed promising antitumor activity warranting further...
因此,需要确定新的生物标志物,来确定早期HER2阳性乳腺癌新辅助靶向治疗的精准获益人群。 近日,来自浙江大学医学院附属邵逸夫医院肿瘤科的研究人员在Pathology Research and Practice杂志上发表了一项研究,通过免疫组化评估HER2蛋白表达水平与早期HER2阳性乳腺...
参考文献: [1]Nader-Marta G,Martins-Branco D,de Azambuja E.How we treat patients with metastatic HER2-positive breast cancer.ESMO Open.2022 Feb;7(1):100343. [2]Prat A,Guarneri V,ParéL,et al.A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast can...
为了指导LM患者的治疗决策,临床医生可以考虑预后居里评分(Curie score),该评分综合了体能状态、LM诊断前接受化疗(CT)方案的数量和激素受体状态;对于来源于BC的LM患者,乳腺分级预后评估(Breast-GPA)在BC脑转移(BCBM)患者中得到验证。其它预后因素包括对治疗的初始反应和诊断时脑脊液(CSF)中的蛋白水平。需要注意的是,尽...
We evaluated the proportion of HER2-positive cases (score 3 overexpression/score 2 plus fluorescence in situ hybridization (FISH) amplification) in a consecutive series of 2163 patients. According to immunohistochemical analysis of HER2 expression, using Herceptest and FDA criteria, 839 cases had ...
有研究对 4 种 PR 抗体(1E2、EP2、SP2、16)免疫组化染色及比较,显示兔单克隆抗体 1E2平均着色细胞数、平均百分比评分、平均染色强度、平均 A-score 明显高于其他 3 个抗体,是较理想的 PR 抗体。 3、HER2 人表皮生长因子受体家族包括4位成员——HER1、HER2、HER3和HER4。作为跨膜蛋白,它们可以在细胞表面与...
超越CTS5 评分:新型列线图精准预测 HR+/HER2+乳腺癌患者长期预后 《Current Problems in Cancer》:Beyond CTS5 score: A novel nomogram predicting long-term prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
免疫治疗在晚期胃癌一线治疗中的地位还不清楚。KEYNOTE-062研究[13]评估了PD-L1联合阳性评分(Combined Positive Score, CPS)≥1的晚期胃癌患者中帕博利珠单抗单药,帕博利珠单抗+化疗和化疗的疗效。 KEYNOTE-062是一项3期随机研究。763名患者随机接受上述一种方案治疗。主要终点是CPS≥1和≥10的患者的OS和PFS。
Using Combined Positive Score (CPS) at baseline to identify PD-L1 protein expression, 39.5% of patients had a CPS of < 1%, 48.8% had a CPS of ≥ 1%, 11.6% had a CPS of ≥ 10% and 11.6% of patients did not undergo a primary tumor PD-L1 status at diagnosis. Usi...